Search Results
12 protocol(s) meet the specified criteria
102756Open  
Testing the Addition of the Oral Medication Ibrutinib to Autologous Stem Cell Transplantation for Patients with Relapsed Diffuse Large B-Cell Lymphoma

102932Open  
Phase I Trial of MEDI-570 in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

103123Open  
Multicenter, Phase I, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, Efficacy, and Pharmacokinetics in Patients with Advanced Malignancies

103706Open  
Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies

76853Open  
Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

85518Open  
Dose-Escalation Study of Selinexor (KPT-330), a Selective Inhibitor of Nuclear Export, and Ibrutinib, a Bruton Tyrosine Kinase Inhibitor, in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma

87238Open  
Phase I/II Study of Intratumoral G100 Therapy in Patients with Follicular Non-Hodgkin Lymphoma

87799Open  
Phase I Dose-Ranging Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MRG-106 following Local Intratumoral and Subcutaneous Injection in Patients with Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Sub-Type

87891Open  
Phase II Clinical Trial Evaluating Ibrutinib Maintenance following Intensive Induction for Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

89837Open  
Phase I, Open-Label, Dose-Escalation Study of SGN-CD19B in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

90576Open  
Phase I, Open-Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection to Patients with Advanced/Metastatic Solid Tumors or Lymphomas

99122Open  
Phase II, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement